Birgit  Girshick net worth and biography

Birgit Girshick Biography and Net Worth

Birgit Girshick joined Charles River in 1989 and held positions of increasing responsibility in the Company’s Research Models & Services and Avian Vaccine Services businesses. In 2004, Ms. Girshick was promoted to General Manager of the Avian Vaccine Services business. She was named Corporate Vice President, Global Biopharmaceutical Services (now Biologics Testing Solutions), in 2010. In 2013, Ms. Girshick was promoted to Corporate Senior Vice President, Research Models and Biologics Testing Solutions. In 2016, Ms. Girshick assumed responsibility for leading the WIL integration, and in October 2016, was named head of the global Discovery Services business.

In 2018, Ms. Girshick was promoted to Corporate Executive Vice President overseeing the Discovery, Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services businesses. In 2021, she also assumed responsibility for the company’s Cell and Gene Therapy CDMO business. In October 2021, Ms. Girshick was promoted to Chief Operating Officer, and assumed the additional oversight of the Research Models and Services business, where she began her Charles River career in 1989. In the Chief Operating Officer role, Ms. Girshick is responsible for leading the Company’s global business units, which includes guiding their strategic direction, driving operational excellence and growth, maintaining client and partnership relationships, leading the organization’s digital transformation and integrating acquisitions. She is a member of the company’s Executive Committee.

Ms. Girshick received a B.A. degree from Eastern Connecticut State University and an M.B.A. degree from the University of Rhode Island. She also received a certificate from the Advanced Management Program from Massachusetts Institute of Technology’s Sloan School of Management.

What is Birgit Girshick's net worth?

The estimated net worth of Birgit Girshick is at least $10.18 million as of November 20th, 2023. Ms. Girshick owns 44,449 shares of Charles River Laboratories International stock worth more than $10,180,154 as of April 26th. This net worth approximation does not reflect any other investments that Ms. Girshick may own. Additionally, Ms. Girshick receives an annual salary of $1,280,000.00 as VP at Charles River Laboratories International. Learn More about Birgit Girshick's net worth.

How old is Birgit Girshick?

Ms. Girshick is currently 54 years old. There are 4 older executives and no younger executives at Charles River Laboratories International. The oldest executive at Charles River Laboratories International is Mr. James C. Foster J.D., Chairman, CEO & President, who is 73 years old. Learn More on Birgit Girshick's age.

What is Birgit Girshick's salary?

As the VP of Charles River Laboratories International, Inc., Ms. Girshick earns $1,280,000.00 per year. The highest earning executive at Charles River Laboratories International is Mr. James C. Foster J.D., Chairman, CEO & President, who commands a salary of $2,660,000.00 per year. Learn More on Birgit Girshick's salary.

How do I contact Birgit Girshick?

The corporate mailing address for Ms. Girshick and other Charles River Laboratories International executives is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. Charles River Laboratories International can also be reached via phone at (781) 222-6000 and via email at [email protected]. Learn More on Birgit Girshick's contact information.

Has Birgit Girshick been buying or selling shares of Charles River Laboratories International?

Birgit Girshick has not been actively trading shares of Charles River Laboratories International during the last ninety days. Most recently, on Monday, November 20th, Birgit Girshick bought 1,322 shares of Charles River Laboratories International stock. The stock was acquired at an average cost of $187.82 per share, with a total value of $248,298.04. Following the completion of the transaction, the chief operating officer now directly owns 44,449 shares of the company's stock, valued at $8,348,411.18. Learn More on Birgit Girshick's trading history.

Who are Charles River Laboratories International's active insiders?

Charles River Laboratories International's insider roster includes William Barbo (VP), Robert Bertolini (Director), Stephen Chubb (Director), Victoria Creamer (EVP), James Foster (CEO), Birgit Girshick (VP), Michael Knell (CAO), Deborah Kochevar (Director), Joseph LaPlume (EVP), George Massaro (Director), Shannon Parisotto (EVP), David Smith (CFO), and Richard Wallman (Director). Learn More on Charles River Laboratories International's active insiders.

Are insiders buying or selling shares of Charles River Laboratories International?

During the last year, Charles River Laboratories International insiders bought shares 3 times. They purchased a total of 7,942 shares worth more than $1,447,729.04. During the last year, insiders at the medical research company sold shares 7 times. They sold a total of 23,211 shares worth more than $5,481,396.41. The most recent insider tranaction occured on February, 29th when EVP Victoria L Creamer sold 5,000 shares worth more than $1,268,500.00. Insiders at Charles River Laboratories International own 1.3% of the company. Learn More about insider trades at Charles River Laboratories International.

Information on this page was last updated on 2/29/2024.

Birgit Girshick Insider Trading History at Charles River Laboratories International

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/20/2023Buy1,322$187.82$248,298.0444,449View SEC Filing Icon  
2/16/2023Sell3,205$254.39$815,319.9541,038View SEC Filing Icon  
9/13/2021Sell81$442.19$35,817.3930,025View SEC Filing Icon  
4/6/2021Sell18,311$302.61$5,541,091.7130,059View SEC Filing Icon  
2/19/2021Sell1,675$293.92$492,316.0031,680View SEC Filing Icon  
8/20/2020Sell933$213.51$199,204.8322,852View SEC Filing Icon  
5/12/2020Sell780$165.74$129,277.2021,837View SEC Filing Icon  
12/9/2019Sell1,051$145.55$152,973.0518,728View SEC Filing Icon  
11/13/2019Sell1,499$137.23$205,707.7725,459View SEC Filing Icon  
7/17/2018Sell3,978$119.90$476,962.2018,999View SEC Filing Icon  
3/6/2018Sell9,893$109.10$1,079,326.3026,470View SEC Filing Icon  
See Full Table

Birgit Girshick Buying and Selling Activity at Charles River Laboratories International

This chart shows Birgit Girshick's buying and selling at Charles River Laboratories International by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Charles River Laboratories International Company Overview

Charles River Laboratories International logo
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Read More

Today's Range

Now: $229.03
Low: $227.39
High: $230.86

50 Day Range

MA: $253.48
Low: $226.78
High: $273.43

2 Week Range

Now: $229.03
Low: $161.65
High: $275.00

Volume

322,036 shs

Average Volume

551,216 shs

Market Capitalization

$11.80 billion

P/E Ratio

24.87

Dividend Yield

N/A

Beta

1.4